- A Case of Acute Pancreatitis Caused by Bortezomib in a Patient with Multiple Myeloma
-
Lim JH, Hwang KB, Lim BH, Jeong YH, Sohn KC, Kim TH
- KMID: 2448488
- Korean J Pancreas Biliary Tract.
- 2015 Jul;20(3):136-139.
- doi: 10.15279/kpba.2015.20.3.136
Bortezomib is a proteasome inhibitor used for the treatment of patients with multiple myeloma. Recently, several case reports about acute pancreatitis caused by Bortezomib were published in the international literature.... -
- CITED
-
- Close
- SHARE
-
- Close
- Reversible Heart Failure after Bortezomib Treatment in a Patient with Multiple Myeloma
-
Song J, Kim H, Shin S, Kim I, Oh D, Chong S
- KMID: 2269134
- Korean J Med.
- 2015 Apr;88(4):459-463.
- doi: 10.3904/kjm.2015.88.4.459
Bortezomib (Velcade(R)) came into the spotlight as a target therapy for multiple myeloma. It acts through reversible inhibition of intracellular proteasomes, which triggers apoptosis, with relative selectivity for malignant cells.... -
- CITED
-
- Close
- SHARE
-
- Close
- Bortezomib-induced Histiocytoid Sweet Syndrome
-
Oh YJ, Lew BL, Sim WY
- KMID: 2359680
- Korean J Dermatol.
- 2016 Nov;54(9):739-743.
Sweet syndrome is an acute febrile neutrophilic dermatosis predominantly characterized by fever, an elevated neutrophil count, and erythematous skin lesions comprising plaques and nodules that mainly appear on the upper... -
- CITED
-
- Close
- SHARE
-
- Close
- Two Cases of Bortezomib-induced Drug Eruption Presenting as Multiple Plaques on the Trunk
-
Choe YS, Kim EJ, Na JI
- KMID: 2245828
- Korean J Dermatol.
- 2016 Jan;54(1):47-51.
Bortezomib (Velcade(R)) is proteasome inhibitor that is used as a first-line therapy for multiple myeloma. It can cause gastrointestinal, hematologic, and neuromuscular side effects, and a cutaneous reaction is one... -
- CITED
-
- Close
- SHARE
-
- Close
- Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis
-
Lee DM, Kim IY, Seo MJ, Kwon MR, Choi KS
- KMID: 2389293
- Exp Mol Med.
- 2017 Aug;49(8):e365.
- doi: 10.1038/emm.2017.112
The proteasome inhibitor, bortezomib, is ineffective against many solid tumors. Nutlin-3 is a potent antagonist of human homolog of murine double minute 2/p53 interaction exhibiting promising therapeutic anti-cancer activity. In... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Cutaneous Plasmacytoma Treated with Bortezomib and Radiotherapy
-
Jeong KH, Yoon HJ, Lee MH
- KMID: 2247932
- Korean J Dermatol.
- 2009 Apr;47(4):483-486.
Multiple myeloma is a hematologic malignancy characterized by the proliferation of monoclonal plasma cells that produce monoclonal immunoglobulins. Cutaneous involvement is very uncommon in patients with multiple myeloma. It usually... -
- CITED
-
- Close
- SHARE
-
- Close
- The Effect of Bortezomib on the Management of Immediate Postoperative Refractory Antibody-Mediated Rejection after Kidney Transplantation
-
Kim SJ, Jun KW, Hwang JK, Chung BH, Yang CW, Moon IS, Kim JI, Kim MH
- KMID: 2421280
- J Korean Soc Transplant.
- 2018 Sep;32(3):49-56.
- doi: 10.4285/jkstn.2018.32.3.49
BACKGROUND: Bortezomib has been used to treat antibody-mediated rejection (AMR) that usually develops after kidney transplantation (KT). Although it has been used in various clinical situations, it is difficult to... -
- CITED
-
- Close
- SHARE
-
- Close
- Bortezomib inhibits the survival and proliferation of bone marrow stromal cells
-
Kim HY, Moon JY, Ryu H, Choi YS, Song IC, Lee HJ, Yun HJ, Kim S, Jo DY
- KMID: 2172772
- Blood Res.
- 2015 Jun;50(2):87-96.
- doi: 10.5045/br.2015.50.2.87
BACKGROUND: Bortezomib is widely used for the treatment of multiple myeloma. Bone marrow stromal cells (BMSCs) endow myeloma cells with survival and growth advantages. However, the influence of bortezomib on... -
- CITED
-
- Close
- SHARE
-
- Close
- Bortezomib Induced Tumor Lysis Syndrome in Multiple Myeloma
-
Yu S, Ryu SW, Kim KH, Kim SH, Lee NS, Park SK, Won JH
- KMID: 2317696
- Soonchunhyang Med Sci.
- 2013 Jun;19(1):31-33.
The tumor lysis syndrome (TLS) commonly occurs in the lymphoproliferative disorder, either spontaneously or in response to therapy. TLS is uncommon in multiple myeloma. However, with the use of bortezomib... -
- CITED
-
- Close
- SHARE
-
- Close
- Huge Cutaneous Involvement of Multiple Myeloma
-
Chae WS, Jung HN, Lee DB, Suh HS, Choi YS
- KMID: 2246479
- Korean J Dermatol.
- 2013 Dec;51(12):1004-1006.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Poor prognostic significance of Mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myeloma
-
Ahn JS, Rew SY, Yang DH, Jung SH, Kang SJ, Kim MY, Lee SS, Kim YK, Kim HJ, Lee JJ
- KMID: 2270724
- Blood Res.
- 2013 Mar;48(1):35-39.
- doi: 10.5045/br.2013.48.1.35
BACKGROUND: Bortezomib administration leads to a transient decrease in CD4+ T cells, increasing the susceptibility to opportunistic infections. The activation and proliferation of CD4+ T cells are particularly important in... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Bortezomib-Associated Cutaneous Lymphocytic Vasculitis
-
Lee KJ, Kim JE, Park HJ, Lee JY, Cho BK
- KMID: 2247734
- Korean J Dermatol.
- 2009 Dec;47(12):1392-1396.
Bortezomib (Velcade(R)) is a newly developed chemotherapeutic agent that is mainly used for the treatment of multiple myeloma. It is a selective and reversible inhibitor of proteasome, which is a... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Drug-Induced Hepatitis due to Bortezomib in Multiple Myeloma
-
Kim Y, Kim KY, Lee SH, Chung YY, Yahng SA, Lee SE, Park G, Min CK
- KMID: 2168011
- Immune Netw.
- 2012 Jun;12(3):126-128.
- doi: 10.4110/in.2012.12.3.126
We report on a case of severe hepatotoxicity in a 52-year-old male with multiple myeloma (MM) who had received bortezomib therapy. At patient presentation, liver enzymes were normal, but started... -
- CITED
-
- Close
- SHARE
-
- Close
- The risk factors for herpes zoster in bortezomib treatment in patients with multiple myeloma
-
Yi YS, Chung JS, Song MK, Shin HJ, Seol YM, Choi YJ, Cho GJ, Lee GW, Moon JH, Hwang IH, Ahn KH, Lee HS, Shin KH, Hwang JM
- KMID: 2252061
- Korean J Hematol.
- 2010 Sep;45(3):188-192.
- doi: 10.5045/kjh.2010.45.3.188
BACKGROUND: Bortezomib has significant activity in treating multiple myeloma (MM). The risk of herpes zoster (HZ) has been reported to increase significantly with bortezomib treatment, but the predisposing factors for... -
- CITED
-
- Close
- SHARE
-
- Close
- Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients
-
Lee SS, Jung SH, Ahn JS, Kim YK, Cho MS, Jung SY, Lee JJ, Kim HJ, Yang DH
- KMID: 2373738
- J Korean Med Sci.
- 2016 Jul;31(7):1160-1163.
- doi: 10.3346/jkms.2016.31.7.1160
Peripheral T cell lymphoma (PTCL) is a heterogeneous group of aggressive lymphomas with poor prognosis. Elderly (age ≥ 65years) patients generally have impaired bone marrow function, altered drug metabolism, comorbidities,... -
- CITED
-
- Close
- SHARE
-
- Close
- Bortezomib Therapy Followed by Autologous Stem Cell Transplantation in POEMS Syndrome
-
Kang SH, Lee JY, Chun SH, Park HW, Min CK, Kim CC, Kim M, Kim Y
- KMID: 2252180
- Korean J Hematol.
- 2008 Sep;43(3):145-149.
- doi: 10.5045/kjh.2008.43.3.145
BACKGROUND: The acronym POEMS refers to polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes. Increased levels of cytokines, including vascular endothelial growth factor (VEGF), appear to play a pathogenic role.... -
- CITED
-
- Close
- SHARE
-
- Close
- The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation
-
Lee J, Kim BS, Park Y, Lee JG, Lim BJ, Jeong HJ, Kim YS, Huh KH
- KMID: 2345894
- Yonsei Med J.
- 2015 Nov;56(6):1638-1642.
- doi: 10.3349/ymj.2015.56.6.1638
PURPOSE: Recently, bortezomib has been used to treat antibody-mediated rejection (AMR) refractory to conventional treatment such as plasmapheresis, intravenous immunoglobulin, and rituximab. The authors aimed to describe their experiences when... -
- CITED
-
- Close
- SHARE
-
- Close
- Bortezomib Reduces Neointimal Hyperplasia in a Rat Carotid Artery Injury Model
-
Kim KS, Kim SY, Choi JH, Joo SJ, Kim DW, Cho MC
- KMID: 2224814
- Korean Circ J.
- 2013 Sep;43(9):592-599.
- doi: 10.4070/kcj.2013.43.9.592
BACKGROUND AND OBJECTIVES: The ubiquitin-proteasome system is the major intracellular protein degradation pathway in the eukaryotic cells. Bortezomib inhibits 26S proteasome-induced I-kappaBalpha degradation and suppresses nuclear factor-kappa B (NF-kappaB) activation.... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment of Refractory Antibody-mediated Rejection with Bortezomib in a Kidney Transplant Recipient: A Case Report
-
Lee JY, Yoo JY, Kwon SH, Jeon JS, Noh H, Han DC, Song D, Jin SY
- KMID: 2202536
- J Korean Soc Transplant.
- 2014 Jun;28(2):87-90.
- doi: 10.4285/jkstn.2014.28.2.87
Antibody-mediated rejection (ABMR) is associated with poor renal allograft survival. It shows poor response to conventional treatment with plasmapheresis, rituximab, and intravenous immunoglobulin. Bortezomib, a proteasome inhibitor used for treatment... -
- CITED
-
- Close
- SHARE
-
- Close
- Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
-
Lee SR, Choi H, Lee BH, Kang KW, Yu ES, Kim DS, Park Y, Choi CW, Kim BS, Sung HJ
- KMID: 2463492
- Korean J Intern Med.
- 2019 Nov;34(6):1333-1346.
- doi: 10.3904/kjim.2018.144
BACKGROUND/AIMS: Bortezomib plus melphalan-prednisone (VMP) is a standard treatment for multiple myeloma, particularly for patients who are ineligible for high-dose therapy. However, early discontinuation or treatment modification is often needed... -
- CITED
-
- Close
- SHARE
-
- Close
